IL-17 Contributes to Cell-Mediated Defense against Pulmonary *Yersinia pestis* Infection

Jr-Shiuan Lin, Lawrence W. Kummer, Frank M. Szaba and Stephen T. Smiley

*J Immunol* 2011; 186:1675-1684; Prepublished online 20 December 2010; doi: 10.4049/jimmunol.1003303

http://www.jimmunol.org/content/186/3/1675

References  This article cites 45 articles, 23 of which you can access for free at:
http://www.jimmunol.org/content/186/3/1675.full#ref-list-1

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

Subscription  Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

*average
IL-17 Contributes to Cell-Mediated Defense against Pulmonary Yersinia pestis Infection

Jr-Shiuang Lin, Lawrence W. Kummer, Frank M. Szaba, and Stephen T. Smiley

Pneumonic plague is one of the world’s most deadly infectious diseases. The causative bacterium, Yersinia pestis, has the potential to be exploited as a biological weapon, and no vaccine is available. Vaccinating B cell-deficient mice with D27-PLpxL, a live attenuated Y. pestis strain, induces cell-mediated protection against lethal pulmonary Y. pestis challenge. In this article, we demonstrate that prime/boost vaccination with D27-PLpxL confers better protection than prime-only vaccination. The improved survival does not result from enhanced bacterial clearance but is associated with increased levels of IL-17 mRNA and protein in the lungs of challenged mice. The boost also increases pulmonary numbers of IL-17–producing CD4 T cells. Interestingly, most of these cells simultaneously produce canonical type 1 and type 17 cytokines; most produce IL-17 and TNF-α, and many produce IL-17, TNF-α, and IFN-γ. Neutralizing IL-17 counteracts the improved survival associated with prime/boost vaccination without significantly impacting bacterial burden. Thus, IL-17 appears to mediate the enhanced protection conferred by booster immunization. Although neutralizing IL-17 significantly reduces neutrophil recruitment to the lungs of mice challenged with Y. pestis, this impact is equally evident in mice that receive one or two immunizations with D27-PLpxL, suggesting it cannot suffice to account for the improved survival that results from booster immunization. We conclude that IL-17 plays a yet to be identified role in host defense that enhances protection against pulmonary Y. pestis challenge, and we suggest that pneumonic plague vaccines should aim to induce mixed type 1 and type 17 cellular responses.

Yersinia pestis, the Gram-negative facultative intracellular bacterium that causes plague, is one of the world’s most deadly human pathogens. Plague has killed hundreds of millions of people during three major pandemics (1–3). The disease is naturally transmitted from rodent reservoirs to humans via fleabites, which typically cause the bubonic form of plague, characterized by a painful swelling of lymph nodes draining the site of infection (2, 3). If left untreated, Y. pestis bacteria can disseminate to the blood and cause septicemic plague. If the bacteria colonize the lungs, the disease may progress to pulmonary plague, which can be spread from person to person through respiratory droplets. Pneumonic plague is a rapidly progressing disease and usually fatal unless treated with antibiotics soon after symptom onset (3). However, antibiotic-resistant isolates of Y. pestis have been described (4). In addition, scientists developed techniques to effectively aerosolize Y. pestis during the Cold War (5), raising concern that antibiotic-resistant Y. pestis strains could be exploited as deadly biological weapons of terror (6).

Tremendous effort has been dedicated to the development of plague countermeasures, but safe and effective vaccines for pneumonic plague are not currently available (7). Although F1/LcrV-based vaccines induce high-titer Ab responses and provide substantial protection in mouse models of pneumonic plague (7, 8), they have failed, thus far, to fully protect nonhuman primates (8, 9). The variable efficacy of these vaccines in primates raises the possibility that Abs may not suffice to protect humans against pneumonic plague. Moreover, F1-deficient Y. pestis strains retain their virulence and pathogenic Y. pestis species can express multiple LcrV variants, some of which may evade cross-protective immunity (7, 8). Thus, the F1/LcrV subunit vaccines in development may fail to fully protect humans against weaponized plague.

Recent studies suggest that TNF-α and IFN-γ, cytokine products of type 1 cellular immunity, also contribute to defense against Y. pestis infection (10–16). Despite inducing high-titer Abs, F1/LcrV immunization poorly protects STAT4-deficient mice, which are impaired for type 1 immune responses (10). Moreover, wild-type mice actively immunized with F1/LcrV (13), or passively immunized with F1- or LcrV-specific mAb (13, 14), succumb to pulmonary Y. pestis challenge if TNF-α and IFN-γ are neutralized at the time of infection. TNF-α and IFN-γ also contribute to the T cell-mediated protection conferred by vaccinating B cell-deficient μMT mice with attenuated Y. pestis (11, 12). Together, these studies suggest that next-generation plague vaccines should aim to induce both Y. pestis-specific Ab and type 1 cellular immunity (8).

The proinflammatory cytokine IL-17 (also known as IL-17A) also contributes to antibacterial defense, and CD4 T cells can produce IL-17 (17–21). These Th17 cells also produce IL-17F, IL-21, IL-22, IFN-γ, TNF-α, IL-6, and GM-CSF under certain circumstances (21–24). A number of studies have established that Th17 cells contribute to the host defense against bacterial pathogens by inducing expression of antimicrobial factors and recruiting neutrophils to mucosal surfaces (19–21, 25–29). In this article, we demonstrate that vaccination with live attenuated Y. pestis induces IL-17–producing CD4 T cells, and that IL-17 contributes to defense against pulmonary Y. pestis challenge. Interestingly, this IL-
17–mediated protection does not appear to result entirely from enhanced bacterial clearance. Although the precise mechanism of protection conferred by IL-17 remains to be determined, these findings suggest that pneumonic plague vaccines should aim to induce production of mixed type 1 and type 17 cellular responses.

Materials and Methods

Mice

B cell-deficient (µMT; B6.129S2-Igh-6szm1gig) mice on the C57BL/6 background were purchased from The Jackson Laboratory (Bar Harbor, ME) and then bred in the specific-pathogen-free Trudeau Institute Animal Breeding Facility after embryo rederivation. Experimental mice were matched for age and sex, and cared for according to Trudeau Institute Animal Care and Use Committee guidelines.

Bacteria

Pigmentation-negative Y. pestis strain D27 was generously provided by Robert Brubaker (Michigan State University, East Lansing, MI). Y. pestis bacilli from frozen glycerol stocks were grown overnight at 26°C with continuous shaking in Bacto heart infusion broth supplemented with 2.5 mM CaCl2. After dilution to an OD of 0.1 at 620 nm, they were regrown for 3–4 h at 26°C; washed with saline, quantified by OD measurement, and resuspended in saline at the desired concentration. The number of bacteria in the inoculating dose was confirmed by plating. The vaccine strain D27-LpxL, was prepared by transforming strain D27 with plasmid pLpxL (12), which was generously provided by Egil Lien (University of Massachusetts Medical School, Worcester, MA). D27-LpxL was stored, grown and prepared as described for strain D27 in medium supplemented with 100 µM/ml ampicillin.

Vaccination and challenge

In all instances, bacteria were administered in a volume of 30 µl saline applied to the nostrils of mice lightly anesthetized by isoflurane. For the “prime-only” groups, mice were vaccinated intranasally with 2 × 10^6 CFU D27-LpxL and rested for 60 d before challenge. For the “prime/boost” groups, mice were primed intranasally with 2 × 10^6 CFU D27-LpxL, boosted with the same dose of D27-LpxL 30 d later, and rested for another 60 d before challenge. For challenge, mice were infected intranasally with 20 or 200 median lethal doses (MLD) of Y. pestis strain D27. The intranasal MLD of strain D27 is \( \sim 1 \times 10^3 \) CFU when the bacteria are grown and administered as described earlier (12).

Measurement of bacterial burden and survival

At the indicated days after challenge infection, mice were euthanized by carbon dioxide narcosis. Liver and lung tissues were harvested and homogenized in saline. Serial dilutions of the homogenates were plated on blood agar plates, incubated at 26°C for 48 h, and then bacterial CFU were counted. In all survival studies, recumbent animals were considered moribund and euthanized.

Flow cytometry

Lungs were perfused with saline containing heparin, minced, and then digested with collagenase and DNase (11). Viable cells were counted using trypan blue exclusion and stained immediately with anti–CD4-FITC (clone RM4-5), anti–CD8-PerCP (clone 53-6,7), anti–CD4-PE (clone 145-2C11), anti–CD107a-PerCP, anti–CD122-biotin, and anti–CD8-biotin. Cells were stained with anti–CD11c-PE, anti–CD69-PE, anti–CD3-allophycocyanin (clone 145-2C11), and anti–CD11c-PE (clone 53-6,7), followed by fixation, permeabilization, and intracellular staining with anti–IL-17-PE, anti–IFN-γ-PE, anti–TNF-α-PE, and anti–CD4-allophycocyanin (clone RM4-5) and anti–CD8–PerCP (clone 53-6,7), followed by fixation, permeabilization, and intracellular staining with anti–TNF-α-FITC (clone MP6-XT22), anti–IFN-γ-PE, and anti–IL-17-PE (clone H129.19). Data were collected on a Becton Dickinson FACSCanto II and analyzed using FlowJo version 8.8 software (Tree Star). In all experiments, forward and side scatter gating was used to exclude dead cells and debris. Other gating (e.g., CD4^+) is described in the figure legends. The fluorochrome-labeled anti–TNF-α and anti–IFN-γ mAbs were purchased from eBioScience (San Diego, CA), and all other staining mAbs were purchased from BD Bioscience (San Diego, CA).

Cytokine neutralization

To neutralize TNF-α and IFN-γ, we treated mice with 1 mg mAb specific for TNF-α (clone XT3.11, rat IgG1) and 600 µg mAb specific for IFN-γ (clone XMGI.2, rat IgG1) diluted in PBS and administered i.p. on the day before challenge. Control mice received an equal quantity of isotype-matched rat IgGl1 mAb (clone HRPN). To neutralize IL-17, we treated mice with 150 µg neutralizing mAb specific for IL-17 (clone 50104) diluted in PBS and administered it i.p. on the day before and days 1 and 3 postchallenge. Control mice received an equal amount of isotype-matched control mAb (clone 2A3, rat IgG2a). The IL-17 mAb was supplied by R&D Systems (Minneapolis, MN). All other mAb were supplied by Bio X Cell (West Lebanon, NH).

Measurement of cytokine and chemokine levels

Tissue levels of mRNA-encoding cytokines and chemokines were measured by real-time PCR, normalized to levels of GADPH mRNA, and expressed as fold change relative to the average level measured in naive uninfected mice (30). Levels of cytokine and chemokine protein in bronchoalveolar lavage fluid (BALF) were measured by LumineX technology using a MILLIPLEX MAP 32-plex kit (Millipore, Billerica, MA) according to the manufacturer’s instructions.

Statistics

Statistical analyses were performed using the program Prism 4.0 (GraphPad Software). Survival data were analyzed by log-rank tests. Flow cytometry and real-time PCR data were analyzed by parametric tests (Student t test or one-way ANOVA, as indicated). Bacterial burden was analyzed by nonparametric tests (Mann–Whitney or Kruskal–Wallis, as indicated); CFU less than the detection limit of our assay were assigned values 0.2 log below the detection limit.

Results

Prime/boost vaccination with strain D27-P-LpxL provides better protection against high-dose Y. pestis challenge than does a single vaccination

D27-P-LpxL is a Y. pestis strain engineered to express Escherichia coli LpxL (12), which promotes production of inflammatory, hexa-acylated forms of LPS, thus attenuating D27 by augmenting innate immune responses (31). B cell-deficient mice cannot produce Abs, thus permitting specific investigation of roles for T cells in immune defense against pathogens. Consistent with prior studies (12), Fig. 1A demonstrates that immunizing B cell-deficient µMT mice with live D27-P-LpxL conferred nearly full protection from lethal, low-dose, intranasal challenge (20 MLD) with Y. pestis strain D27 (Fig. 1A). A single immunization with D27-P-LpxL also conferred significant protection from high-dose challenge (200 MLD) with strain D27 (p < 0.005), although more than half of the immunized mice nevertheless succumbed to high-dose challenge (Fig. 1B). With the intent of further improving the protective capacity of cellular immunity, we investigated the efficacy of a prime/boost regimen. B cell-deficient µMT mice were immunized with strain D27-P-LpxL, rested for 30 d, and then boosted with strain D27-P-LpxL. After another 60 d, these “prime/boost” mice were challenged intranasally with either 20 or 200 MLD Y. pestis strain D27, alongside the “prime-only” mice that received one single immunization with D27-P-LpxL. After 20 MLD challenge, both the prime-only and prime/boost mice exhibited >85% survival (Fig. 1A). After 200 MLD challenge, only 37% of the prime-only mice survived, whereas 76% of the prime/boost mice survived (Fig. 1B). The improved protection conferred by prime/boost vaccination was highly significant (p < 0.005).

The booster vaccination does not improve protection by decreasing bacterial burden

Measurements of bacterial burden after 20 and 200 MLD challenge revealed that both the prime-only and prime/boost mice contained fewer bacterial CFU in lung and liver tissue, as compared with

Downloaded from http://www.jimmunol.org/ by guest on June 9, 2022
A booster vaccination with live attenuated 

unvaccinated control mice (both \( p < 0.001; \) Fig. 1C, 1D). However, the number of CFU did not differ significantly between prime-only and prime/boost mice (Fig. 1C, 1D). Subsequently, we examined the kinetics of bacterial growth after 200 MLD challenge in greater detail (Fig. 1E, 1F). At all time points, both the prime-only and prime/boost mice exhibited reduced bacterial burden in lung and liver tissues, as compared with unvaccinated mice. However, the prime-only and prime/boost mice showed comparable bacterial burden at days 3, 4, and 5 after challenge (Fig. 1E, 1F). These data suggest that the improved survival mediated by the booster vaccination does not result from improved control of bacterial growth or dissemination.

**The booster vaccination increases the number of pulmonary CD4 T cells with an activated phenotype**

We previously reported that a single immunization with D27-pLpxL increases the number of CD4 and CD8 T cells with an activated phenotype (CD43hiCD44hi) in the lungs of mice challenged with 20 MLD 

The Journal of Immunology 1677

Downloaded from http://www.jimmunol.org/ by guest on June 9, 2022

FIGURE 1. A booster vaccination with live attenuated 

by guest on June 9, 2022 http://www.jimmunol.org/ Downloaded from
ex vivo activation with plate-bound anti-CD3. Previously, we reported that a single immunization with D27-pLpxL increases the number of CD4 and CD8 T cells capable of producing both TNF-α and IFN-γ after 20 MLD challenge with Y. pestis strain D27 (12). Fig. 3A and 3B demonstrate that few pulmonary CD4 T cells in unvaccinated mice could be stimulated to produce both TNF-α and IFN-γ at day 3 after 200 MLD challenge, and the number of these cells decreased further as the infection progressed. In comparison with unvaccinated mice, the frequency and number of CD4 T cells capable of producing both TNF-α and IFN-γ increased dramatically in mice immunized with D27-pLpxL (Fig. 3A, 3B). In comparison with the prime-only mice, prime/boost mice exhibited significantly increased frequencies (Fig. 3A) and absolute numbers (Fig. 3B) of TNF-α– and IFN-γ–producing CD4 T cells at days 3 and 4, but not day 5, after challenge. The frequency of CD4 T cells producing TNF-α, but not producing IFN-γ, also increased in the boosted mice (Fig. 3C). Notably, the prime-only mice and prime/boost mice did not differ significantly with regard to the number or number of TNF-α– and IFN-γ–producing CD8 T cells (data not shown).

We also measured levels of TNF-α and IFN-γ protein in BALF after challenge with 200 MLD Y. pestis strain D27 (Fig. 3D). Although all of the unvaccinated mice and most of the prime-only mice showed undetectable levels of TNF-α at day 4 after challenge, the prime/boost mice exhibited significantly increased TNF-α levels. In contrast, IFN-γ levels did not differ significantly between the prime-only and prime/boost mice.

To determine whether TNF-α and IFN-γ contribute to protection mediated by booster vaccination, we administered specific mAb that neutralize these cytokines at the time of 200 MLD Y. pestis challenge. Control mice received isotype-matched mAb of irrelevant specificity. As shown in Fig. 3E, neutralizing TNF-α and IFN-γ at the time of challenge almost completely abolished the protection conferred by either prime-only or prime/boost immunization. These findings complement our prior studies reporting that TNF-α and IFN-γ play critical roles during vaccination-mediated protection from pulmonary Y. pestis challenge (11–13). However, it is unclear that the modestly increased numbers of TNF-α and IFN-γ–producing CD4 T cells in the prime/boost mice suffice to account for the improved protection conferred by booster vaccination.

The booster vaccination increases IL-17 production in the lung

When measuring cytokine levels in mice that had been challenged with Y. pestis, we also observed a dramatic and highly significant increase in the amount of IL-17 protein in the BALF collected from the prime/boost mice, as compared with BALF from the prime-only mice (p < 0.001; Fig. 4A). Likewise, real-time PCR revealed that lung tissue collected from the boosted mice contained significantly more IL-17 mRNA than that of prime-only mice (p < 0.001; Fig. 4A).

Flow cytometry revealed that most of the T cells capable of producing IL-17 in the lung at day 4 after 200 MLD challenge expressed CD4 (Fig. 4B), and the frequency of these cells increased substantially in the prime/boost mouse, as compared with the prime-only mouse (Fig. 4C). Specifically, 37% of the CD4 T cells produced IL-17 in the boosted mouse, as compared with only 10% in prime-only mice (Fig. 4C). Kinetic analyses revealed that the prime/boost mouse, in comparison with prime-only mice, harbored significantly increased frequencies of IL-17–producing CD4 T cells at days 3, 4, and 5 after challenge (p < 0.001; Fig. 4D). Absolute numbers of IL-17–producing CD4 T cells in the prime/boost mice were more than 6-fold greater than that of prime-only mice at days 3 and 4 after challenge (Fig. 4E).

The booster vaccination increases the number of pulmonary CD4 T cells capable of producing TNF-α and IFN-γ

We used an intracellular cytokine staining procedure to quantify the number of T cells with the capacity to produce cytokines on
Gating on IL-17–producing CD4 T cells revealed that most of these cells also produced canonical type 1 cytokines; >70% also produced TNF-α, and 28% produced both TNF-α and IFN-γ (Fig. 4F). Interestingly, the frequencies of IL-17–producing CD4 T cells that also produced TNF-α and IFN-γ (i.e., TNF-α+IFN-γ+ cells) did not differ between the prime-only and prime/boost mice (Fig. 4F). Likewise, among the CD4 T cells that did not produce IL-17, frequencies of TNF-α+IFN-γ− cells did not differ between the prime-only and prime/boost mice (Fig. 4F).

In comparison with CD4 T cells, we observed relatively small increases in the frequencies of CD8 T cells capable of producing IL-17 (data not shown). There were significant increases in the number of IL-17–producing CD8 T cells in vaccinated mice as compared with unvaccinated mice (data not shown). However, there were no significant differences between the prime-only and prime/boost mice with regard to the percentages or absolute numbers of IL-17–producing CD8 T cells.

**IL-17 contributes to the protection conferred by booster vaccination**

Given that prime/boost vaccination dramatically increased pulmonary IL-17 levels, we hypothesized that IL-17 may contribute to the improved protection conferred by booster vaccination. To test this hypothesis, we vaccinated mice and then administered a neutralizing mAb specific for IL-17 at the time of challenge. As shown in Fig. 5A, 47% of the prime-only mice treated with control mAb survived a 200 MLD *Y. pestis* challenge. Neutralizing IL-17 reduced the survival of the prime-only mice to 33%. This modest impact of IL-17 neutralization in the prime-only mice did not achieve statistical significance (Fig. 5A). In contrast, prime/boost vaccination resulted in 85% survival, and neutralization of IL-17 in the prime/boost mice reduced survival significantly (*p < 0.05*; Fig. 5B). Notably, the IL-17 neutralization in the prime/boost mice reduced survival rate to 48% (Fig. 5B), which was comparable with the level observed in the prime-only mice treated with control mAb (Fig. 5A). Despite its significant impact on survival, IL-17 neutralization did not significantly affect the bacterial burden in lung and liver tissues of prime/boost mice (Fig. 5C, 5D). Altogether, these data indicate that IL-17 contributes to the improved survival mediated by booster vaccination, but suggest that IL-17

---

**FIGURE 3.** TNF-α and IFN-γ contribute to protection mediated by vaccination with live attenuated *Y. pestis*. B cell-deficient μMT mice were primed (p-only; ▼) or prime/boosted (p/b; ■) with D27-pLpxL, or left unvaccinated (unvac; ○), and then challenged intranasally with 200 MLD *Y. pestis* strain D27, as described in Fig. 1. A and B. At the indicated days after challenge, cells were isolated from lung tissues, restimulated with plate-bound anti-CD3 mAb for 5 h, stained for intracellular cytokines, and analyzed by flow cytometry. The percentage (A) and number (B) of TNF-α+IFN-γ+ CD4 T cells are shown. Data depict the mean and SD of five mice per group, and statistical significance was measured by one-way ANOVA with Bonferroni’s multiple-comparison test. Results are shown for p-only versus p/b. *p < 0.05; **p < 0.01; ***p < 0.001. C. Flow cytometry analysis of cytokine producing CD4+ T cells at day 4 post-challenge. Each plot depicts a concatenation of data from five mice per group. Data shown were gated on CD4+ T cells. The numbers depict the percentage of cells in the indicated quadrant. Similar results were observed in three independent experiments. D. TNF-α and IFN-γ protein levels in BALF collected at day 4 postchallenge. Broken line depicts the limit of detection (6.4 pg/ml); solid bar depicts the median of TNF-α and IFN-γ levels in unvaccinated mice. Statistical significance was measured by nonparametric Kruskal–Wallis with Dunn’s multiple-comparison test. *p < 0.05. E. At the time of challenge, mice received neutralizing mAb specific for TNF-α and IFN-γ (aTNF/IFN) or an isotype-matched mAb (RIG1G1). In comparison with mice treated with isotype-matched mAb, both p-only and p/b mice treated with cytokine-neutralizing mAb exhibited significantly reduced survival (*p < 0.0001; log-rank test; n = 19 for aTNF/IFN-treated groups; n = 9 for RIG1G1-treated groups; data are pooled from 2 independent experiments). ns, not significant.
may not function protectively by reducing bacterial growth or dissemination.

**IL-17 induces CXCL1 expression and recruits neutrophils to the lungs of vaccinated mice**

To investigate how IL-17 contributes to survival after challenge with 200 MLD *Y. pestis*, we examined the cellular composition in the lungs of mice treated with IL-17 neutralizing mAb. Consistent with Figs. 3–5, the boosted mice harbored more CD43^hi^CD44^hi^CD4 T cells (Fig. 6A), TNF-α^+^IFN-γ^+^CD4 T cells (Fig. 6B), and IL-17–producing CD4 T cells (Fig. 6C) than prime-only mice at day 4 after challenge. However, the number of these activated and cytokine-producing CD4 T cells did not differ significantly between mice treated with IL-17 mAb and control mice (Fig. 6A–C).

When examining other cell populations in mice treated with IL-17 neutralizing mAb, we found that the frequency and total number of CD4^+^ cells, CD8^+^ cells, CD3^+^ cells, NK cells, NKT cells, and macrophages in the lungs and spleens of the prime/boost mice were comparable with those of prime-only mice, and IL-17 neutralization did not impact their numbers significantly (data not shown).
CXCL9, CXCL10, CXCL11, G-CSF, CCR4, IFN-γ immunization likewise increased expression of IL-17, IL-22, and lipocalin 2 levels (Fig. 6B). Prime-only and prime/boost vaccinations strongly suggest that the bacterial load per se is not the only cause of mortality in this model. They also suggest that the booster vaccination improves the capacity of mice to survive in the presence of a substantial bacterial burden. We speculate that boosting mice with D27-pLpxL reduces some form of pathology induced by Y. pestis challenge that acts in concert with the bacterial burden to cause mortality.

The boosting regimen significantly increases the numbers of IL-17–producing CD4 T cells in the lung prechallenge (Fig. 6C). Boosting also dramatically increases the numbers of IL-17–producing CD4 T cells in the lung after Y. pestis challenge (Fig. 4, 6C), as well as the levels of IL-17 mRNA and protein (Fig. 4). Neutralizing IL-17 significantly reduces the survival of boosted mice (Fig. 5). In contrast, neutralizing IL-17 does not significantly reduce the survival of prime-only mice (Fig. 5), which produce relatively low levels of IL-17 after Y. pestis challenge (Fig. 4). Thus, IL-17 appears to be a major mediator of the improved survival that results from the boost.

In wild type mice, the protective impacts of cytokines and T cells must be dissociated from the impacts of Abs, which protect against pneumonic plague in passive transfer experiments (13, 14). Thus, in this study, we focused on the μMT mice, where the lack of Ab enables decisive studies of acquired defense mediated by T cells and the cytokines produced by T cells. Importantly, in addition to increasing numbers of IL-17–producing CD4 T cells in the lungs shown). We also did not observe differences in the number of splenic neutrophils in IL-17 mAb-treated mice (data not shown). However, neutralization of IL-17 did significantly, albeit only partially, reduce the number of pulmonary CD11bLy6G neutrophils in both the prime-only and prime/boost mice (p < 0.05 and p < 0.01, respectively; Fig. 6D).

In parallel with studies of the cellular content of the lungs, we used real-time PCR to measure pulmonary levels of mRNA encoding proteins implicated previously in IL-17–mediated biology (IL-17, IL-22, CXCL1, CXCL9, CXCL10, CXCL11, G-CSF, CCR6, CCR4, and lipocalin 2) and generally involved in host defense against bacterial infection (IFN-γ, TNF-α, IL-6, IL-10, IL-1β, inducible NO synthase, IL-12p35, and IL-12p40). Levels of CXCL1, a chemokine known to attract and activate neutrophils, increased 10-fold in both the prime-only and prime/boost mice, and neutralizing IL-17 decreased CXCL1 levels significantly, albeit only partially (Fig. 6E). Prime-only and prime/boost immunization also increased levels of the IL-17–inducible antimicrobial protein lipocalin 2, and neutralization of IL-17 significantly decreased lipocalin 2 levels (Fig. 6F). Prime-only and prime/boost immunization likewise increased expression of IL-17, IL-22, CXCL9, CXCL10, CXCL11, G-CSF, CCR4, IFN-γ, TNF-α, IL-6, IL-10, IL-1β, and IL-12p35; however, neutralizing IL-17 did not significantly impact their expression levels (Fig. 6G–I and data not shown).

Discussion

Over the past 50 years, studies on plague vaccine development have focused largely on Ab-mediated humoral immunity and devoted relatively little attention to cellular defense. Nevertheless, we recently demonstrated that type 1 cellular immunity induced by vaccination with live attenuated strain D27-pLpxL can suffice to protect Ab-deficient mice against lethal pulmonary Y. pestis challenge (12). This study demonstrates that a prime/boost regimen of D27-pLpxL vaccination further improves T cell–mediated defense against pulmonary Y. pestis challenge.

Boosting mice with D27-pLpxL significantly improves survival, even though the bacterial burden does not differ significantly between prime-only and prime/boost mice (Fig. 1). These observations strongly suggest that the bacterial load per se is not the only cause of mortality in this model. They also suggest that the booster vaccination improves the capacity of mice to survive in the presence of a substantial bacterial burden. We speculate that boosting mice with D27-pLpxL reduces some form of pathology induced by Y. pestis challenge that acts in concert with the bacterial burden to cause mortality.

The Journal of Immunology 1681

FIGURE 5. IL-17 contributes to vaccine-mediated protection against pulmonary Y. pestis challenge without impacting bacterial burden. B cell-deficient μMT mice were primed (p-only; triangles) or prime/boosted (p/b; squares) with D27-pLpxL, or left unvaccinated (unvac; circles), and then challenged intranasally with 200 MLD Y. pestis strain D27. At the time of challenge, the mice were treated with neutralizing mAb specific for IL-17 (aIL-17; solid symbols) or an isotype-matched control mAb (RlgG2a; open symbols). In parallel, sex- and age-matched naive mice were challenged with the same dose of strain D27 without mAb treatment (unvac nil). A and B, Survival decreased significantly in p/b mice (B) but not in prime-only mice (A) treated with IL-17 mAb, as compared with mice treated with control mAb (p < 0.05, log-rank test; n = 17–25 mice/group; data pooled from 3 independent experiments). C and D, Bacterial burden at day 4 after challenge. Neutralizing IL-17 modestly increased the bacterial burden in the lungs of prime-only mice but did not significantly affect the pulmonary or hepatic burden in p/b mice. *p < 0.05, Mann–Whitney U test; data are pooled from two independent experiments. Solid bar depicts the median; broken line depicts the limit of detection. ns, not significant.

The boosting regimen significantly increases the numbers of IL-17–producing CD4 T cells in the lung prechallenge (Fig. 6C). Boosting also dramatically increases the numbers of IL-17–producing CD4 T cells in the lung after Y. pestis challenge (Fig. 4, 6C), as well as the levels of IL-17 mRNA and protein (Fig. 4). Neutralizing IL-17 significantly reduces the survival of boosted mice (Fig. 5). In contrast, neutralizing IL-17 does not significantly reduce the survival of prime-only mice (Fig. 5), which produce relatively low levels of IL-17 after Y. pestis challenge (Fig. 4). Thus, IL-17 appears to be a major mediator of the improved survival that results from the boost.
of μMT mice challenged with virulent *Y. pestis* (Fig. 4), boosting similarly expands populations of IL-17–producing CD4 T cells in wild type mice (data not shown).

We previously demonstrated that TNF-α and IFN-γ contribute to protection mediated by humoral and cellular defense against lethal pulmonary *Y. pestis* challenge (12–15). In all those studies, neutralizing TNF-α and IFN-γ significantly increased the bacterial burden. In contrast, neutralizing IL-17 does not significantly compromise the control of bacterial growth in mice challenged with *Y. pestis* (Fig. 5C, 5D). Moreover, IL-17 neutralization selectively impacts the survival of boosted mice (Fig. 5B), whereas neutralizing TNF-α and IFN-γ almost completely abolishes the protection conferred by either prime-only or prime/boost vaccination (Fig. 3E). These observations further suggest that IL-17, not TNF-α or IFN-γ, is a primary contributor to the improved survival conferred by the booster vaccination. Importantly, these findings also indicate that type 1 cytokines and IL-17 protect mice against plague through distinct mechanisms. We suggest that the type 1 responses control bacterial growth and clear the infection, whereas type 17 responses provide critical additional “help” that acts in concert with bacterial control to reduce tissue damage or enhance tissue repair mechanisms, or both. We envision that even a modest reduction in pathology could result in a substantial increase in survival by providing additional time for the immune system to control and clear the infection.

IL-17–mediated protection against pathogens is thought to result, in large part, from increased neutrophil recruitment. IL-17 stimulates granulopoiesis by increasing G-CSF production, and induces expression of the chemokines CXCL1 and CXCL2, which recruit neutrophils to sites of infection. In most of the infection models in which IL-17 plays a critical role in host defense, abrogating IL-17 signaling results in significantly reduced neutrophil recruitment, in turn reducing pathogen clearance (19). Consistent with those prior studies, our data suggest that IL-17 contributes to the recruitment of neutrophils to the lungs of mice challenged with *Y. pestis*, appendix apparently secondary to IL-17–mediated induction of the neutrophil chemoattractant CXCL1 (Fig. 6E). However, neutrophil recruitment, as well as CXCL1 expression, is similar in magnitude in prime-only and prime/boost mice, and the partial reductions in neutrophil numbers and CXCL1 expression that result from IL-17 neutralization are comparable in prime-only and prime/boost mice. Moreover, depleting neutrophils increases the bacterial burden.
in mice challenged with Y. pestis (32–34) (S. Smiley and J. Lin, unpublished data), whereas neutralizing IL-17 does not impact the bacterial burden significantly (Fig. 5). Therefore, in contrast with prior studies where neutrophils were identified as the major cells mediating IL-17-dependent host resistance, our data suggest that IL-17–driven neutrophil recruitment does not account for the improved protection observed in mice boosted with D27-pLpxL.

In addition to recruiting neutrophils, IL-17 reportedly augments recruitment of type 1 T cells during infection (27, 35). Mycobacterial-specific T cells from IL-17–deficient mice display impaired IFN-γ production (35), and neutralizing IL-17 in vaccinated mice during M. tuberculosis challenge significantly reduces the frequency of Ag-specific IFN-γ–producing T cells in the lungs and also inhibits expression of genes encoding the CXCR3 ligands CXCL9, CXCL10, and CXCL11, which contribute to the recruitment of Th1 cells (27). Likewise, IL-17 is required for the generation of protective IFN-γ responses during pulmonary tularemia (26). Although these prior studies suggest IL-17 can contribute to defense against infection, in part, by augmenting type 1 responses, we do not observe such impacts in our model of vaccine-mediated protection against pneumonic plague. Specifically, neutralizing IL-17 during Y. pestis challenge does not significantly impact the number of IFN-γ–producing T cells in the lung (Fig. 6F) or the expression of CXCL9, CXCL10, and CXCL11 (Fig. 6H, 6I, and data not shown). Neutralizing IL-17 also does not impact the expression of two other T cell chemokines, CCL5 and CCL20 (data not shown). Therefore, our data suggest that increased recruitment of Th1 cells does not account for the IL-17–mediated improvement in protection against Y. pestis infection.

IL-17 also reportedly contributes to the formation of mature pulmonary granulomas in mycobacteria-infected mice (35, 36). Specifically, IL-17–deficient mice show normal level of nascent granuloma formation but fail to develop mature granuloma at later stages of infection. Because immunization facilitates formation of granuloma-like structures in the livers of mice challenged with virulent Y. pestis (12, 37, 38), perhaps IL-17 improves the formation of granuloma-like structures in mice immunized with D27-pLpxL. Although preliminary analyses have not revealed obvious distinctions in the hepatic histopathology of prime-only and prime/boost mice, further study is warranted to address this issue.

IL-17–producing CD4 T cells often produce IL-22, a cytokine known to act synergistically or additively with IL-17 to enhance the expression of antimicrobial peptides, promote inflammation, and protect tissue (25, 39–44). However, we could not detect IL-22–producing CD4 cells in this model (data not shown), and we do not observe differences in IL-22 mRNA levels between prime-only and prime/boost mice, or between IL-17 mAb-treated and control mice (Fig. 6G). Nevertheless, IL-17 neutralization suppressed the immunization-induced upregulation of lipocerin 2 (Fig. 6F), an antimicrobial protein whose expression is upregulated synergistically by exposure to IL-22 and IL-17 (25, 39, 45).

TNF-α also synergizes with IL-17 to upregulate expression of lipocerin 2 (46). Interestingly, a large proportion of the IL-17–producing CD4 T cells induced by booster immunization simultaneously produce TNF-α, and many of these cells produce IFN-γ as well (Fig. 4F, 4H). Although TNF-α–producing Th17 cells have been described before (22–24), to our knowledge, this is the first report to implicate cells with a mixed type 1/type 17 in host defense against infection. We also think it notable that these “Th1-17” cells, expanded by intranasal booster immunization with D27-pLpxL, persist at significant levels for at least 60 d (Fig. 4, 6C). In contrast, the Th17 cells induced by intranasal infection with Listeria monocytogenes are short-lived (47). The apparent difference in the longevity of IL-17–producing T cells in these two distinct models of intranasal bacterial infection may reflect the different types of bacteria used, the booster regimen, and/or the different life spans for Th17 and Th1-17 cells. Regardless, our finding that intranasal booster immunization with attenuated bacteria confers robust, long-lived, IL-17–associated protection warrants further studies of the underlying mechanisms and their potential for translation to other vaccine settings.

Although the precise mechanism of IL-17–mediated protection during pulmonary Y. pestis infection remains to be established, our study clearly indicates that IL-17 can contribute significantly to host defense against pneumonic plague. The protection mediated by IL-17 does not seem to result from improved bacterial clearance or neutrophil recruitment, but somehow enables mice to better withstand Y. pestis challenge in the presence of a substantial bacterial load. Regardless of the underlying mechanisms, our findings suggest that mammals with a capacity to efficiently produce and respond to IL-17 may have a greater capacity to combat pneumonic plague. Prior reports demonstrated that vaccine-mediated protection against pulmonary Y. pestis infection strongly benefits from production of TNF-α and IFN-γ (11–15), and this study suggests that pneumonic plague vaccines also should aim to prime production of IL-17. We anticipate that the presence of Y. pestis–specific memory Th1-17 cells with the capacity to produce TNF-α, IFN-γ, and IL-17 will constitute an immunological correlate of protection for the efficacy of human plague vaccines.

Acknowledgments
We thank Debbie Duso for technical assistance and the employees of the Trudeau Institute animal facilities for dedicated care and breeding of the mice used in these studies. We also thank Drs. Robert Brubaker and Egil Lien for generously providing access to Y. pestis strain D27 and plasmid pLpxL, respectively.

Disclosures
The authors have no financial conflicts of interest.

References


